Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Durvalumab/tepotinib

Lack of efficacy and peripheral oedema: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Rubio FS, et al. Efficacy and safety of Tepotinib in advanced Non-Small-Cell Lung Cancer with a confirmed METexon 14 skipping mutation: a case report. Journal of Oncology Pharmacy Practice 29 (Suppl.): 40-41, No. 2, Jun 2023. Available from: URL: http://doi.org/10.1177/10781552231158084 [abstract] Rubio FS, et al. Efficacy and safety of Tepotinib in advanced Non-Small-Cell Lung Cancer with a confirmed METexon 14 skipping mutation: a case report. Journal of Oncology Pharmacy Practice 29 (Suppl.): 40-41, No. 2, Jun 2023. Available from: URL: http://​doi.​org/​10.​1177/​1078155223115808​4 [abstract]
Metadaten
Titel
Durvalumab/tepotinib
Lack of efficacy and peripheral oedema: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41430-8

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Gadodiamide

Case report

Imatinib

Case report

Iron-sucrose